RU99108453A - SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS - Google Patents
SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTSInfo
- Publication number
- RU99108453A RU99108453A RU99108453/04A RU99108453A RU99108453A RU 99108453 A RU99108453 A RU 99108453A RU 99108453/04 A RU99108453/04 A RU 99108453/04A RU 99108453 A RU99108453 A RU 99108453A RU 99108453 A RU99108453 A RU 99108453A
- Authority
- RU
- Russia
- Prior art keywords
- och
- acridine
- together represent
- alkoxy
- alkyl
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- -1 NH 2 Inorganic materials 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- SFHZYISZLYHTSO-UHFFFAOYSA-N 5,6-dihydro-9,10-dimethoxy-3,4-methylendioxybenz[a]acridine Chemical compound C1=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3CCC2=C2OCOC2=C1 SFHZYISZLYHTSO-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VQFJLWXVNWBXIP-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-5,6-dihydrobenzo[a]acridine Chemical compound COC1=C(OC)C=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)C3=NC2=C1 VQFJLWXVNWBXIP-UHFFFAOYSA-N 0.000 claims 1
- MDFXHHPSEAVOHU-UHFFFAOYSA-N 2,3,9,10-tetramethoxybenzo[a]acridine Chemical compound COC1=C(OC)C=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3C=CC2=C1 MDFXHHPSEAVOHU-UHFFFAOYSA-N 0.000 claims 1
- SFCFKCONSQEYJV-UHFFFAOYSA-N 2,3-dimethoxy-5,6-dihydrobenzo[a]acridine Chemical compound C1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)C3=NC2=C1 SFCFKCONSQEYJV-UHFFFAOYSA-N 0.000 claims 1
- ZITDMBBMVWIUEH-UHFFFAOYSA-N 2,3-dimethoxybenzo[a]acridine Chemical compound C1=CC=CC2=CC3=C(C=C(C(OC)=C4)OC)C4=CC=C3N=C21 ZITDMBBMVWIUEH-UHFFFAOYSA-N 0.000 claims 1
- XUQFHMLUQBVNOK-UHFFFAOYSA-N 3,4,9,10-tetramethoxy-5,6-dihydrobenzo[a]acridine Chemical compound COC1=CC=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3CCC2=C1OC XUQFHMLUQBVNOK-UHFFFAOYSA-N 0.000 claims 1
- XOVQEPLYPSNLKH-UHFFFAOYSA-N 3,9,10-trihydroxy-7H-benzo[a]acridin-2-one Chemical compound C1=C(O)C(=O)C=C2C3=CC(C=C(C(=C4)O)O)=C4NC3=CC=C21 XOVQEPLYPSNLKH-UHFFFAOYSA-N 0.000 claims 1
- WPYQPDDHNZJIKS-UHFFFAOYSA-N 3-chloro-9,10-dimethoxy-5,6-dihydrobenzo[a]acridine Chemical compound ClC1=CC=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3CCC2=C1 WPYQPDDHNZJIKS-UHFFFAOYSA-N 0.000 claims 1
- GAWFURWOVNUYIP-UHFFFAOYSA-N 3-chloro-9,10-dimethoxybenzo[a]acridine Chemical compound ClC1=CC=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3C=CC2=C1 GAWFURWOVNUYIP-UHFFFAOYSA-N 0.000 claims 1
- FILGDFWWHCZSIB-UHFFFAOYSA-N 9,10-dimethoxy-5,6-dihydrobenzo[a]acridin-2-amine Chemical compound C1=C(N)C=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3CCC2=C1 FILGDFWWHCZSIB-UHFFFAOYSA-N 0.000 claims 1
- XNLBBUPFCTUTJR-UHFFFAOYSA-N 9,10-dimethoxy-5,6-dihydrobenzo[a]acridine Chemical compound C1=CC=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3CCC2=C1 XNLBBUPFCTUTJR-UHFFFAOYSA-N 0.000 claims 1
- JXFBPUWLYUYUDJ-UHFFFAOYSA-N 9,10-dimethoxybenzo[a]acridine Chemical compound C1=CC=C2C(C=C3C=C(C(=CC3=N3)OC)OC)=C3C=CC2=C1 JXFBPUWLYUYUDJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- JLYVIWHAPNAFFK-UHFFFAOYSA-N Oc1cc2CCc3nc4cc(O)c(O)cc4cc3-c2cc1O Chemical compound Oc1cc2CCc3nc4cc(O)c(O)cc4cc3-c2cc1O JLYVIWHAPNAFFK-UHFFFAOYSA-N 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000005528 methosulfate group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (22)
в которой R1 и R2 представляют независимо ОН, NO2, NH2, галоген, NHCO(C1-C8) алкил или (C1-С8)алкокси; или R1 и R2 вместе представляют -ОСН2О-;
R3 представляет Н;
R5 и R6 представляют независимо Н, ОН, NO2, NH2, галоген, NHCO(C1-C8) алкил или (С1-С8)алкокси; или R5 и R6 вместе представляют -ОСН2О-, и
R7 представляет Н или (C1-C8)алкил; или R1, R2, R3, R5 и R6 независимо представляют Н, ОН, NO2, NH2, галоген, NHCO(C1-C8)алкил или (С1-С8)алкокси; R1 и R2 вместе представляют -ОСН2O-; R2 и R3 вместе представляют -ОСН2O-; R5 и R6 вместе представляют -ОСН2O-; и R7 представляет Н или (C1-C8)алкил; при условии, что один из R1 и R2 представляет (C1-C8)алкокси, или R1 и R2 вместе представляют -ОСН2O-; или R1, R5 и R6 независимо представляют Н, OH, NO2, NH2, галоген, NHCO(C1-C8) алкил или (C1-C8)алкокси; R2 и R3 вместе представляют -ОСН2О-; и R7 представляет Н или (C1-C8)алкил;
или его фармацевтически приемлемая соль.1. The compound of formula II
in which R 1 and R 2 are independently OH, NO 2 , NH 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; or R 1 and R 2 together represent —OCH 2 O—;
R 3 is H;
R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; or R 5 and R 6 together represent —OCH 2 O—, and
R 7 is H or (C 1 -C 8 ) alkyl; or R 1 , R 2 , R 3 , R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; R 1 and R 2 together represent —OCH 2 O-; R 2 and R 3 together represent —OCH 2 O-; R 5 and R 6 together represent —OCH 2 O-; and R 7 is H or (C 1 -C 8 ) alkyl; with the proviso that one of R 1 and R 2 is (C 1 -C 8 ) alkoxy, or R 1 and R 2 together represent —OCH 2 O-; or R 1 , R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; R 2 and R 3 together represent —OCH 2 O—; and R 7 is H or (C 1 -C 8 ) alkyl;
or its pharmaceutically acceptable salt.
в которой R1 и R2 представляют независимо NO2, галоген, NHCO(C1-C8) алкил или (C1-C8)алкокси; или R1 и R2 вместе представляют -ОСН2О-;
R3 представляет Н;
R5 и R6 представляют независимо Н, ОН, NO2, NН2, галоген, NHCO(C1-C8)алкил или (С1-С8)алкокси; или R5 и R6 вместе представляют -ОСН2О-, и
R7 представляет Н или (C1-C8)алкил; или R1, R2, R3, R5 и R6 независимо представляют Н, OH, NO2, NH2, галоген, NHCO-(C1-C8)алкил или (C1-C8)алкокси; R1 и R2 вместе представляют -OCH2O-; R2 и R3 вместе представляют -OCH2O-; R5 и R6 вместе представляют -OCH2O-; и R7 представляет Н или (C1-C8)алкил; при условии, что один из R1 и R2 представляет (C1-C8)алкокси, или R1 и R2 вместе представляют -OCH2O-; или R1, R5 и R6 независимо представляют H, ОН, NO2, NН2, галоген, NНСО(С1-С8)алкил или (С1-С8)алкокси; R2 и R3 вместе представляют -OCH2O-; и R7 представляет Н или (C1-C8)алкил;
или его фармацевтически приемлемая соль.2. The compound of the formula
in which R 1 and R 2 are independently NO 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; or R 1 and R 2 together represent —OCH 2 O—;
R 3 is H;
R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHCO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; or R 5 and R 6 together represent —OCH 2 O—, and
R 7 is H or (C 1 -C 8 ) alkyl; or R 1 , R 2 , R 3 , R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHCO- (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; R 1 and R 2 together represent -OCH 2 O-; R 2 and R 3 together represent -OCH 2 O-; R 5 and R 6 together represent -OCH 2 O-; and R 7 is H or (C 1 -C 8 ) alkyl; provided that one of R 1 and R 2 is (C 1 -C 8 ) alkoxy, or R 1 and R 2 together are —OCH 2 O-; or R 1 , R 5 and R 6 are independently H, OH, NO 2 , NH 2 , halogen, NHSO (C 1 -C 8 ) alkyl or (C 1 -C 8 ) alkoxy; R 2 and R 3 together represent -OCH 2 O-; and R 7 is H or (C 1 -C 8 ) alkyl;
or its pharmaceutically acceptable salt.
2,3,9,10-тетраметокси-5,6-дигидробенз[а]акридин,
2,3-диметокси-9,10-метилендиокси-5,6-дигидробенз[а]акридин,
9,10-диметокси-5,6-дигидробенз[а]акридин,
2,3-диметокси-5,6-дигидробенз[а]акридин,
5,6-дигидро-9,10-диметокси-3,4-метилендиоксибенз[а]акридин,
5,6-дигидро-3,4,9,10-тетраметоксибенз[а]акридин,
2-амино-9,10-диметокси-5,6-дигидробенз[а]акридин,
3-хлор-9,10-диметокси-5,6-дигидробенз[а]акридин,
2,3,9,10-тетраметоксибенз[а]акридин,
2,3-диметокси-9,10-метилендиоксибенз[а]акридин,
9,10-диметоксибенз[а]акридин,
2,3-диметоксибенз[а]акридин,
3-хлор-9,10-диметоксибенз[а]акридин,
2,3,9,10-тетраметокси-7-метилбенз[а]акридиний метосульфат,
2,3,9,10-тетраметокси-7-метил-5,6-дигидробенз[а]акридиний метосульфат,
2,3,9,10-тетрагидрокси-5,6-дигидробенз[а]акридин или
2,3,9,10-тетрагидроксибенз[а]акридин;
или его фармацевтически приемлемая соль.14. Connection
2,3,9,10-tetramethoxy-5,6-dihydrobenz [a] acridine,
2,3-dimethoxy-9,10-methylenedioxy-5,6-dihydrobenz [a] acridine,
9,10-dimethoxy-5,6-dihydrobenz [a] acridine,
2,3-dimethoxy-5,6-dihydrobenz [a] acridine,
5,6-dihydro-9,10-dimethoxy-3,4-methylenedioxybenz [a] acridine,
5,6-dihydro-3,4,9,10-tetramethoxybenz [a] acridine,
2-amino-9,10-dimethoxy-5,6-dihydrobenz [a] acridine,
3-chloro-9,10-dimethoxy-5,6-dihydrobenz [a] acridine,
2,3,9,10-tetramethoxybenz [a] acridine,
2,3-dimethoxy-9,10-methylenedioxybenz [a] acridine,
9,10-dimethoxybenz [a] acridine,
2,3-dimethoxybenz [a] acridine,
3-chloro-9,10-dimethoxybenz [a] acridine,
2,3,9,10-tetramethoxy-7-methylbenz [a] acridium methosulfate,
2,3,9,10-tetramethoxy-7-methyl-5,6-dihydrobenz [a] acridine methosulfate,
2,3,9,10-tetrahydroxy-5,6-dihydrobenz [a] acridine or
2,3,9,10-tetrahydroxybenz [a] acridine;
or its pharmaceutically acceptable salt.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/026,511 | 1996-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99108453A true RU99108453A (en) | 2001-02-20 |
RU2174116C2 RU2174116C2 (en) | 2001-09-27 |
Family
ID=
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA010094B1 (en) * | 2004-12-22 | 2008-06-30 | Ле Лаборатуар Сервье | NEW BENZO[b]PYRANO[[3.2-h]ACRIDIN-7-ONE CINNAMATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA010094B1 (en) * | 2004-12-22 | 2008-06-30 | Ле Лаборатуар Сервье | NEW BENZO[b]PYRANO[[3.2-h]ACRIDIN-7-ONE CINNAMATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100766A1 (en) | QUINOLIN-2-ON-SUBSTITUTED HETEROAARYNE DERIVATIVES USED AS ANTI-TUMOR AGENTS | |
RU92004336A (en) | WATER-SOLUBLE DERIVATIVES OF CAMPTOTECINE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING ENZYM TOOPOISOMERS, INTERMEDIATE PRODUCTS | |
EA200100954A1 (en) | CAMPTOTECINE DERIVATIVES, possessing anti-tumor activity | |
RU2000128058A (en) | ECTEINASCIDINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND METHOD FOR TREATING TUMORS | |
RU2000127751A (en) | ANTI-TUMOR MEDICINE | |
IS2387B (en) | Anti-tumor agents | |
CA2368653A1 (en) | Z-styryl sulfone anticancer agents | |
RU96111012A (en) | PROCEDURES OF DERIVATIVES PAKLITAKSELA | |
EA200100716A1 (en) | METHOD OF PREVENTION OF BREAST CANCER | |
ES8706139A1 (en) | Coumarin derivatives, pharmaceutical compositions containing the same, and the use thereof in the treatment of cancer. | |
RU96105419A (en) | NEW BISNAFTALIMIDES FOR CANCER TREATMENT | |
ATE390923T1 (en) | TOPOISOMERASE TOXICANTS | |
ATE81655T1 (en) | CEPHEM COMPOUNDS AND PROCESSES FOR THEIR PRODUCTION. | |
EP0351255A3 (en) | Derivatives of û2-(4-piperidinyl)methyl¨-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy | |
RU2005106863A (en) | ANTITUMOR ANALOGUES OF LAMELLARINE | |
BG103735A (en) | Method for the preparation of substituted thiazolidindions | |
IL160082A0 (en) | Quinoline derivatives and use thereof as antitumor agents | |
RU99108453A (en) | SUBSTITUTED HETEROCYCLES AS ANTI-TUMOR AGENTS | |
RU94011565A (en) | THIOXANTENONE COMPOUNDS, THEIR USE, ANTI-SMALL COMPOSITION | |
DE69330601T2 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
RU93053036A (en) | α, ω -DIRYLALKANE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE INDICATED DERIVATIVES | |
EA199800464A1 (en) | SYNERGISTIC IMMUNOSUPRESSOR COMPOSITION CONTAINING 2,2'-BI-1H-PYRROL COMPOUND | |
RU99100107A (en) | DERIVATIVES OF DIBENZOOXAZEPINE AND DIBENZODIOXEPINE AND THEIR APPLICATION AS ANTI-TUMOR AGENTS | |
TR200200017T2 (en) | Benzofuran derivatives | |
RU99113432A (en) | NEW DERIVATIVES OF PHENANTRIDINIA |